Medicine
Qbrelis 1 mg/mL oral solution
Qbrelis 1 mg/mL oral solution is a prescription medicine containing Lisinopril for oral use, marketed by Azurity Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Protect from freezing and excessive heat. Store at controlled room temperature…
Key facts
- Active ingredient (INN)
- Lisinopril
- Brand
- Qbrelis
- Strength
- 1 mg/mL
- Dosage form
- Oral solution
- Route
- Oral
- Packs
- 150 mL
- Marketing authorisation holder
- Azurity Pharmaceuticals
- Manufacturer
- Azurity Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Protect from freezing and excessive heat. Store at controlled room temperature 20°C-25°C (68°F-77°F) in a tightly closed container.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- C09AA03 Lisinopril
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 29 August 2016
- Identifiers
- RxCUI 1806884, 1806890DailyMed set ID 9f6e4e57-a489-4b36-b093-b93865d3717cNDC 52652-3001Application NDA208401
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 150 mL in 1 bottle | 52652-3001-1 | Azurity Pharmaceuticals | 29 August 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 29 December 1987 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Lisinopril
Clinical summary
Lisinopril is an angiotensin converting enzyme inhibitor indicated for treatment of hypertension in adults and pediatric patients 6 years of age and older, among other approved uses. It is available as tablets and oral solution. MedsAcross supplies Lisinopril for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LisinoprilFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Zestril prescribing information (Upsher-Smith Laboratories) · U.S. National Library of Medicine, DailyMed
Need Qbrelis 1 mg/mL oral solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.